ARWR vs NOC · rev $829.4M vs P/E 17, rev $20.76B
Arrowhead Pharmaceuticals Inc (ARWR) versus Northrop Grumman Corporation (NOC) — a side-by-side from cached financials, not a winner call.
Arrowhead Pharmaceuticals Inc (ARWR) is a biotechnology company listed on US.
Northrop Grumman Corporation (NOC) is a aerospace & defense company listed on NYSE.
Latest reported ARWR revenue for 2025-09-30 was $829.4M. Net income was $30.1M. Revenue was up 23258.2% from 2024-09-30 to 2025-09-30. ARWR currently screens at market cap $10.59B.
Latest reported NOC revenue for 2026-06-30 was $20.76B. Net income was $1.97B. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
ARWR currently screens at market cap $10.59B. NOC currently screens at market cap $78.14B and trailing P/E 17.2.
Not investment advice. Open the ARWR and NOC stock pages for the full models.
Not investment advice.